Preparation and properties of inhalable nanocomposite particles for treatment of lung cancer

Tomoda, Keishiro; Ohkoshi, Takumi; Hirota, Keiji; Sonavane, Ganeshchandra S.; Nakajima, Taro; Terada, Hiroshi; Komuro, Masahito; Kitazato, Kenji; Makino, Kimiko

doi:10.1016/j.colsurfb.2009.02.001

Cited by 87 publications

(48 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…145 Similarly, PLGA-based anticancer drug (TAS-103)-loaded NPs were prepared with an average particle size of 200 nm, which resulted in enhanced antitumor efficacy in lungs tumor. 146 Moreover, doxorubicin contained in poly(butylcyanoacrylate) NPs were also effective against lung tumor.…”

Section: Lung Tumormentioning

confidence: 99%

Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors

Din

Aman

Ullah³

et al. 2017

IJN

1,118

481

View full text Add to dashboard Cite

Nanotechnology has recently gained increased attention for its capability to effectively diagnose and treat various tumors. Nanocarriers have been used to circumvent the problems associated with conventional antitumor drug delivery systems, including their nonspecificity, severe side effects, burst release and damaging the normal cells. Nanocarriers improve the bioavailability and therapeutic efficiency of antitumor drugs, while providing preferential accumulation at the target site. A number of nanocarriers have been developed; however, only a few of them are clinically approved for the delivery of antitumor drugs for their intended actions at the targeted sites. The present review is divided into three main parts: first part presents introduction of various nanocarriers and their relevance in the delivery of anticancer drugs, second part encompasses targeting mechanisms and surface functionalization on nanocarriers and third part covers the description of selected tumors, including breast, lungs, colorectal and pancreatic tumors, and applications of relative nanocarriers in these tumors. This review increases the understanding of tumor treatment with the promising use of nanotechnology.

show abstract

Section: Lung Tumormentioning

confidence: 99%

Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors

Din

Aman

Ullah³

et al. 2017

IJN

1,118

481

View full text Add to dashboard Cite

show abstract

“…Nanocoposites showed a MMAD of 2.5 mm and FPF of 14% when tested with the capsule-based Jethaler device (Hitachi Ltd., Japan). In animal experiments, the nanocomposites provided an elevated lung concentration of the drug in the lungs up to 8 h, while plasma concentrations were find to be barely detectable, probably as a consequence of the rapid systemic metabolism (Tomoda et al, 2009).…”

Section: Dry Powder Inhalersmentioning

confidence: 95%

Loco-regional administration of nanomedicines for the treatment of lung cancer

et al. 2015

View full text Add to dashboard Cite

Lung cancer poses one of the most significant challenges to modern medicine, killing thousands every year. Current therapy involves surgical resection supplemented with chemotherapy and radiotherapy due to high rates of relapse. Shortcomings of currently available chemotherapy protocols include unacceptably high levels of systemic toxicity and low accumulation of drug at the tumor site. Loco-regional delivery of nanocarriers loaded with anticancer agents has the potential to significantly increase efficacy, while minimizing systemic toxicity to anticancer agents. Local drug administration at the tumor site using nanoparticulate drug delivery systems can reduce systemic toxicities observed with intravenously administered anticancer drugs. In addition, this approach presents an opportunity for sustained delivery of anticancer drug over an extended period of time. Herein, the progress in the development of locally administered nanomedicines for the treatment of lung cancer is reviewed. Administration by inhalation, intratumoral injection and means of direct in situ application are discussed, the benefits and drawbacks of each modality are explored.

show abstract

“…Hepatitis B surface antigen [80] Dry powders High mucosal immune response in the lungs Rifampicin [81] Dry powders Sustained plasma therapeutic drug levels Drug persistence in lung tissue and cells Nano-embedded microparticles siRNA [64] Dry powders Preservation of siRNA structural integrity Efficient in vitro gene silencing No cytotoxicity (H1299 cells) TAS- 103 anticancer drug [82] Dry powders Enhanced cytotoxicity against A549 cells High local drug concentration Tobramycin [83] Dry powders…”

Section: Prolonged Hypoglycaemic Effect In Diabeticmentioning

confidence: 99%

“…[82,83,125,126] Trehalose and lactose were tested as inert carriers for rifampicin-loaded PLGA nanoparticles. [125,126] Formulation studies were useful to assess the effect of the preparation conditions -inlet temperature, size and weight ratio of primary NPs -on the properties of NEMs.…”

Section: Nano-embedded Microparticlesmentioning

confidence: 99%

Engineered PLGA nano- and micro-carriers for pulmonary delivery: challenges and promises

Ungaro

d’Angelo

Miro

et al. 2012

Journal of Pharmacy and Pharmacology

159

View full text Add to dashboard Cite

Objectives The aim of this review is to summarize the current state-of-the-art in poly(lactic-co-glycolic acid) (PLGA) carriers for inhalation. It presents the rational of use, the potential and the recent advances in developing PLGA microparticles and nanoparticles for pulmonary delivery. The most promising particle engineering strategies are discussed, highlighting the advantages along with the major challenges for researchers working in this field.

show abstract

Preparation and properties of inhalable nanocomposite particles for treatment of lung cancer

Cited by 87 publications

References 21 publications

Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors

Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors

Loco-regional administration of nanomedicines for the treatment of lung cancer

Engineered PLGA nano- and micro-carriers for pulmonary delivery: challenges and promises

Contact Info

Product

Resources

About